Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (June 2009)
22 slides from Zydus Lifesciences's investor presentation, June 2009
Slide 1: Cadila Healthcare Ltd. Investor Presentation
Cadila Healthcare Ltd. Investor Presentation J June 2009 Dr. Sharvil Patel, Dy. Managing Director 1
Slide 2: A Snapshot
A Snapshot One of the oldest and the 5th largest in the Indian formulations market worth over $7.5 bn (Source : ORG IMS MAT Mar Mar-09). 09). Operations in US, Europe, Japan, Latin America, CIS, Africa and Asia Pacific. International sales in generic markets contribute to over 33% of revenues.
Slide 3: Priorities achieved: 2008-09
Priorities achieved : 2008-09 Strategic forays in key 9 Acquired Laboratories Combix to enter Spain and acquired majority stake in Simayla markets Pharmaceuticals, South Africa Continued research focus 9 Invested over 6% of revenue on research. Filed IND ZYT1 with DCGI and USFDA Strengthening the 9
Slide 4: Financial highlights
Financial highlights # Net Profit and EPS exclude Exceptional Items All INR numbers in this presentation have been converted into USD at exchange rate of USD 1 = INR 46 4
Slide 5: State of the art facilities and infrastructure
State of the art facilities and infrastructure Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Goa Sikkim Baddi API, Dabhasa Finished Dosage Form, API, Ankleshwar (USFDA approved) Moraiya (USFDA Approved) (USFDA Approved) Pantoprazole Intermediates Cytotoxic Injectables Fine Chemic
Slide 6: Core business areas and Revenue break-up (FY 08-09)
Core business areas and Revenue break-up (FY 08-09) Revenue break-up by segment Revenue break-up break up by region 6
Slide 7: 5th largest in Indian pharma market
5th largest in Indian pharma market with over $ 260 Mio. sales Leading positions in key segments – CVS, Therapeutic Area-wise Sales Break-up of GI, Female Healthcare and Respiratory Branded Formulations (FY 08-09) (participated (p p market segments) g ) 15 brands feature amongst the top 300 Neut
Slide 8: International formulations: two-fold focus
International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets which constitute 22 % of which contribute to 11 % of global sales g global sales g 9 US - Zydus Pharmaceuticals USA Inc. 9 Brazil – 9 Europe • Branded - Quimica e Pharmaceutica Nikkho
Slide 9: One of the fastest growing generic companies in US
One of the fastest growing generic companies in US Gross Sales Started operations in 2005 and adopted a “Customer Centric Model” 23 products launched. launched 8 -10 10 products to be added every year. Products enjoy 5 - 25% market share Focusing on delivery based, difficult to make products
Slide 10: Over 2.5% market share in participated French market; Entered Spain
Over 2.5 % market share in participated French market;; Entered Spain p Strong presence in Eur 2.3 bn French market Gross Sales Rated one of the fastest growing companies in France by IMS Launched >150 presentations (~75 molecules) in France Acquired Laboratories Combix in 2008 to enter Eur 0.7
Slide 11: Strategies for Japan - world's 2nd largest market
Strategies for Japan - world’s 2nd largest market Market valued at $ 3 bn, growing at ~12%, with very low generic penetration of ~5% in value terms, 17% in volume terms (IGPA) Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufacturing facility in FY 07-08 Pl
Slide 12: Sales up by 20% in the Brazilian pharma market
Sales up by 20% in the $ 12bn Brazilian pharma market growing at 15-18% pp.a. a Gross Sales Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06 Filed dossiers for 45 products so far. 19 have been approvedd andd 12 products d t hhave bbeen llaunched h d Acq
Slide 13: Exports to emerging markets grew by >30%
Exports to emerging markets grew by >30% in last 4 years y Gross Sales Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa, Middle East and CIS regions Focus on rapidly growing markets of Russia, South Africa, Taiwan and Philippines No.1 Indian company in Uganda
Slide 14: Zydus Wellness – A market leader with iconic and niche consumer brands
Zydus Wellness – A market leader with iconic and niche consumer brands Restructured consumer business with de-merger of consumer business from Cadila Healthcare into Carnation in FY 08-09. C Company now renamed d as Z Zydus d W Wellness ll Ltd Ltd. 14
Slide 15: A pioneer in the low calorie sweetener segment and skincare
A pioneer in the low calorie sweetener segment and a trendsetter in skincare products Sugar Free – India India’s s largest selling sugar substitute with market share of >75% (Source : AC Nielsen). Growing at CAGR of 25% for last 3 years, the brand recorded sales of ~$ 17 Mio. in FY 08-09 Every
Slide 16: Unlocking value through win-win alliances
Unlocking value through win-win alliances Zydus Nycomed JV – most successful contract manufacturing JV in India State-of-the-art API mfg. plant for Pantoprazole i t intermediates di t Expanded scope - more APIs to be sourced by Nycomed from this JV Zydus Hospira - JV for oncology injectables
Slide 17: Ongoing Investment in Newer Portfolios
Ongoing Investment in Newer Portfolios Worth $ 180 bn Zydus New Portfolio Mid term Zydus New Portfolio • Biogenerics Biogenerics: 40 bn Near term • Transdermal: 10 bn • Vaccine: 22 bn Oral • Pulmonary: 20 bn • Topical: 16 bn • Transdermal: 10 bn • One of the leading player • Injectables: 17 bn in re
Slide 18: A scientific talent pool of 850 and investing over 6% on research
A scientific talent pool of 850 and investing over 6% of the turnover on research Talent Pool of ~850 Scientists Zydus Research Centre (ZRC) Located L t d iin Ah Ahmedabad d b d Generics/ Developmental Focus on NME Research, 335 scientists Biologicals & NDDS Pharmaceutical Technology Centre NME
Slide 19: Dedicated facility for NME research: Zydus Research Centre
Dedicated facility for NME research : Zydus Research Centre Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation Facility for target identification to pre-clinical research / early clinical development 2nd company in India to be accredited by AAALAC (Association for Assessment and Acc
Slide 20: Highlights: Annual Results FY 08-09
Highlights : Annual Results FY 08-09 USD Mio. Consolidated Growth 2008-09 2007-08 y-y% Domestic Sales 357 324 10.4% E Exports t Sales S l 277 190 45 5% 45.5% Total Gross Sales 634 514 23.4% Total Operating Income 636 505 26.0% EBIDT 132 100 32 2% 32.2% EBIDT % to Total Income Net Profit # 71 58 23.7
Slide 21: Our Vision
Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020. 21
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. state e ts The e Company Co
Cadila Healthcare — Investor Presentation (June 2009) on 6ix